~~<i id='BE7F12366E'><strike id='BE7F12366E'><tt id='BE7F12366E'><pre id='BE7F12366E'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

focus

author：focus 2025-08-26 03:42:23 - browse：83

Eli Lilly said Friday that it will acquire Dermira, a small biotech developing drugs for chronic skin conditions, for $1.1 billion.

The centerpiece of the deal is the Dermira drug called lebrikizumab that aims to treat people suffering from moderate-to-severe atopic dermatitis, the most common form of eczema, a disease characterized by inflamed, itchy, and scaly skin.

Phase 3 clinical trials of lebrikizumab in atopic dermatitis are underway. If successful, the drug could compete against Dupixent, which has grown into a commercial blockbuster for Regeneron Pharmaceuticals and Sanofi.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： STAT Summit: GSK CEO on pharma giant's new direction

hotspot

explore

hotspot

focus

ThebacteriumA.baylyiwasengineeredtodetectacommoncancermutation.CourtesyofJosephineWrightDanWorthley,

WSS

2023 STAT Wunderkinds: get to know the winners

Researchers explore possible ties between long Covid, menopause

What to know about the judge who will handle the Trump case

STAT Summit: GSK CEO on pharma giant's new direction

Timeline: How the deadly wildfires took over Maui day by day

Eli Lilly expects to double planned employment in Boston center

entertainment

focus

hotspot

Bright Health sells Medicare Advantage business to Molina

Biden administration begins canceling student loan debt for 804,000 borrowers

Novavax promises a turnaround & Lilly roils the obesity market

Medicare reduced heart disease by changing how it pays doctors

Medical records are filled with copy

Senate committee scrutinizes Medicare Advantage brokers

The cancer drug shortage isn’t new — and neither are the solutions

FDA struggles to regulate food additives, sometimes for decades

State Dept. review finds Biden bears some blame for Afghanistan failures

NIH confirmation hearing shows politicization of research

explore

The EU Joint Clinical Assessment needs to live up to its promise

Solve the antibiotic resistance crisis with preventive drugs

UnitedHealth’s board chair also owns a personal investment firm

Dozens dead from Maui wildfires: What we know about the victims

Indictment alleges Trump's ex

STAT Readout Newsletter: Today's biggest biotech updates

hotspot

hotspot

focus

focus